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OBJECTIVES: Phaeochromocytoma is a rare tumour, which is benign but metabolically functional,
with a potential for malignancy. Surgical resection is the primary treatment. The purpose of this study
was to identify the presenting features, diagnostic tests and appropriate surgical approaches for
phaeochromocytoma.
METHODS: Retrospective analysis was performed on 26 patients with phaeochromocytoma who
were admitted to General Surgery, Department of Postgraduate Institute of Medical Education and
Research, Chandigarh, India from 1993 to 1999.
RESULTS: Of the 26 patients, 15 were males and 11 were females. Their ages ranged from 13 to 60
years, with a peak phaeochromocytoma incidence in the second decade of life. Two patients had
phaeochromocytoma as a manifestation of multiple endocrine neoplasia type 2 syndrome (MEN-2).
Hypertension was present in 92% of patients. Six (23%) patients had extra-adrenal phaeochromocytoma.
The incidence of bilateral tumour was 25% of adrenal tumour and 11.5% had malignant
phaeochromocytoma.
The diagnostic measurements were: 1) plasma catecholamines, 2) 24-hour urinary vanillylmandelic
acid and 3) fractionated urinary catecholamines. Computed tomography of the abdomen was
extremely accurate in diagnosing phaeochromocytoma (92% accuracy). Magnetic resonance imaging
was performed in 2 patients with 100% accuracy. Preoperatively, all the patients were put on alpha
adrenergic blocking agents to control blood pressure for varying periods of time. The transabdominal
midline approach was used in all cases with excellent results. There was no surgical mortality. All the
resected specimens were subjected to histopathological examination and phaeochromocytoma was
subsequently confirmed.
CONCLUSION: If preoperative diagnosis and localization of phaeochromocytoma is accurate,
surgical resection can be done with minimal morbidity and mortality. (Asian J Surg 2002;25(2):139–44)
INTRODUCTION
Phaeochromocytomas are rare tumours arising from
neuroectodermal cells of the adrenal medulla and from
other extra-adrenal sites. Although phaeochromocytomas
are rare in the general population (incidence, 0.005 % to
0.1%), the incidence is quite high in screened hyper-
tensives, in referral centres.1 Phaeochromocytoma pro-
duces excessive catecholamines which are released into
the circulation and cause the accompanying symptoms.
These tumours are potentially lethal if untreated, but they
can be cured by surgical resection and are also amenable
to pharmacological control.
The presenting clinical signs and symptoms, and bio-
chemical testing can almost diagnose or exclude most
phaeochromocytomas. Tests for phaeochromocytoma
are based on detecting abnormally increased levels of
catecholamines or catecholamine metabolites in urine or
blood.2–4 Computed tomography (CT) and magnetic reso-
nance imaging (MRI) have emerged as the optimal non-
invasive imaging methods for phaeochromocytoma.5,6
Metaiodobenzylguanidine (MIBG) scanning is very help-
ful in localizing pheochromocytomas and for functional
Address reprint requests to Dr. Lileswar Kaman,
Assistant Professor, Department of Surgery,
Postgraduate Institute of Medical Education and
Research, Changdigarh-160012, India.
Fax: (91 172) 744401
Date of acceptance: 11th September 2001




©Excerpta Medica Asia Ltd
Vol 25 • No 2 • April 2002140
KAMAN AND OTHERS
characterization of the tumour.7 Surgical resection of
unprepared phaeochromocytomas has great potential for
intraoperative and postoperative complications. The use
of alpha-adrenergic blockade agents along with more
advanced anaesthetic management has made resection of
phaeochromocytoma safer. In the present report, we
evaluate our experience with phaeochromocytoma since
1993.
PATIENTS AND METHODS
The medical records of all patients with the diagnosis
of phaeochromocytoma, who underwent operations at
the Postgraduate Institute of Medical Education and
Research, Chandigarh, India from 1993 to 1999 were
retrospectively reviewed. Analyses of patients' age, sex,
family history, associated conditions and presenting symp-
toms were made. Results of biochemical tests (24 hour
vanillylmandelic acid [VMA], fractionated urinary cat-
echolamines and plasma catecholamines) were tabulated
before operation. Preoperative anatomical localization of
phaeochromocytoma was done by CT and MRI. All the
resected specimens were subjected to histopathological
examination.
DEMOGRAPHY/ASSOCIATED CONDITIONS
Of the 26 patients who had surgery, 15 were males and
11 were females. Ages ranged from 13 to 60 years, with
the median incidence in the second decade of life.
Twenty-two (75%) patients were between 10 and 40 years
of age. Two patients had phaeochromocytoma as a
manifestation of multiple endocrine neoplasia type 2A
syndrome (MEN 2A). Three patients had malignant phaeo-
chromocytoma, which was diagnosed on the basis of
proven metastasis to non-chromaffin tissues.
CLINICAL PRESENTATION
The most common presenting symptoms were epi-
sodes of headache, palpitation and sweating. Ninety-
two percent of patients presented with hypertension.
Sustained hypertension was present in 10 (42%) and
paroxysmal hypertension was present in 14 (58%).
This distinction between paroxysmal hypertension and
sustained hypertension was not always clear cut and
the episodes were not always distinguishable. Seven
out of 26 patients presented with pain and four patients
had an abdominal mass. Three patients presented with
generalised, tonic-clonic seizures. The duration of
symptoms varied from 1 month to 10 years before
presentation.
BIOCHEMICAL INVESTIGATIONS
Once phaeochromocytoma was suspected clinically,
biochemical testing was carried out for demonstration of
increased urinary excretion of catecholamines and their
metabolites. Urinary 24-hour VMA and free urinary cat-
echolamines (noradrenaline [NA] and adrenaline [A])
levels were estimated. The level of 24-hour urinary VMA
was determined in all 26 patients and was elevated in 22
(85%) of the patients (normal value: 1–8 mg%/24 hours).
Urinary fractionated catecholamines (NA and A) were
determined in 20 patients, out of whom 12 (60%) had
raised levels (normal values: NA ≤ 66 mg and A ≤ 24 mg).
The analysis of fractionated plasma catecholamines were
carried out under controlled conditions in 20 patients.
They were raised in 16 (80%) of the patients (normal
values: NA ≤ 1.6 ng/ml and A ≤ 0.4 ng/ml).
LOCALIZATION
Once the diagnosis of phaeochromocytoma was
biochemically confirmed, localization of the tumour
was done by CT and MRI. CT diagnosis had an ex-
tremely accurate diagnostic rate of 92%. It failed to
pick up two tumours that were situated in the organ of
Zuckerkandl and in the para-aortic region. MRI was
done in two patients where phaeochromocytoma was
diagnosed accurately.
PATHOLOGICAL FINDINGS
Twenty patients (77%) were found to have adrenal
gland tumours and six (23%) patients had extra-adrenal
tumours. Multiple tumours were found in two patients.
Out of the 20 adrenal gland tumours, 10 (50%) were
situated in the right side, five (25%) were situated on the
left and five (25%) were bilateral. The most common
extra-adrenal site was the organ of Zuckerkandl, fol-
lowed by the para-aortic location. Three tumours were
malignant — malignancy being defined by the presence
of metastatic disease. Macroscopically, the tumours
varied considerably in size, but most were about 5 cm
or more in diameter. Bigger tumours were associated
with cystic necrosis and haemorrhage into the central
portion.
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PREOPERATIVE PREPARATION
The preoperative management was directed towards
control of hypertension, adequate alpha blockade and
correction of functional hypovolaemia. A non-selective
alpha adrenergic receptor blocker, phenoxybenzamine
hydrochloride, was used in 17 patients and a specific
alpha-1-adrenergic receptor blocker, prazosin
hydrochloride, was used in nine patients in adjusted
doses for various durations of time (7–21 days). Beta-
blocking agents atenolol and propranolol were used in
eight patients for tachycardia after adequate alpha block-
ade was achieved. The calcium channel blocker,
nifedipine was used for control of blood pressure in
addition to alpha blockers in 12 patients.
ANAESTHESIA
Adequate sedation was given to all patients before
they were taken to the preoperative room, where liberal
anxiolytics and sedation were given to avoid apprehen-
sion before undergoing general anaesthesia. Central
venous pressure and arterial lines were used routinely in
all cases. Several anaesthetic agents were used in our
institute. Enflurane was used in most of the patients.
Significant tachycardia was noted in most of the cases.
Blood pressure fluctuation was varied and wide. Intra-
operative hypertension was controlled with sodium
nitroprusside. Once the tumour was resected, blood,
plasma or crystalloid was given as indicated by the
patient’s central venous pressure.
OPERATIVE APPROACH
We used a midline trans-abdominal approach in all
cases. This approach helped in assessing the whole
abdomen, including the opposite adrenal gland, the or-
gan of Zuckerkandl and the para-aortic region. All the
areas of chromaffin tissue were examined systematically
and finally, the site under suspicion for the tumour was
approached last in order to avoid blood pressure
fluctuation. Our strategy for phaeochromocytoma exci-
sion was simple. If there was a single unilateral tumour,
same- side adrenalectomy with tumour excision was
performed. In cases of bilateral tumours, a small part of the
adrenal gland on the smaller side was left behind after
excision of the bilateral tumour and contralateral
adrenalectomy. In cases of MEN 2, we did bilateral total
adrenalectomy. In cases of extra-adrenal tumour, the
tumour was excised completely with careful examination
of both adrenal glands. Tumour debulking was done in
three cases of malignant phaeochromocytoma. One pa-
tient was put on postoperative combination chemotherapy,
with limited success.
MORBIDITY AND MORTALITY
Out of the 26 patients, six (23%) had various
complications, which were managed successfully with-
out mortality. One patient with a para-aortic extra-
adrenal tumour had aortic injury along with splenic
injury, which was repaired at the same time. One patient
had inferior vena cava injury, which was repaired
primarily. Other complications included wound
infection, pneumonia, urinary tract infection and
prolonged ileus. One patient required immediate re-
exploration to ligate the bleeding right adrenal vein.
Two patients developed immediate postoperative
cardiac arrhythmias which responded to anti-
arrhythmics. The average hospital stay was 19 days.
FOLLOW-UP
Four patients were lost to follow-up. In a median of 26
months' follow-up, three patients with malignancy died at
3 months, 9 months and 14 months, respectively. Of the
remaining 19 patients, four (21%) had persistent hyper-
tension without any evidence of phaeochromocytoma.
Five patients (26%) required a lower dose of antihyperten-
sive and 10 patients (53%) were free from hypertension.
DISCUSSION
Management of phaeochromocytoma has undergone
tremendous improvement since 1927, when Mayo
performed the first successful resection of a
phaeochromocytoma in North America.8 The single most
critical element in the management of phaeo-
chromocytoma is simply to seriously consider it in the
differential diagnosis when appropriate, and to do a
screening test for it.9 The incidence of phaeochromocytoma
in the general population is 0.005% to 0.1%.1 The inci-
dence of phaeochromocytoma increases many-fold in
a screened population of young hypertensives, with
MEN 2A and MEN 2B, von Recklinghausen's neu-
rofibromatosis and von Hippel Lindau syndrome.10 The
peak incidence of phaeochromocytoma occurs during
the fourth and fifth decades of life and the ratio of males
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to females is roughly equal.11 In our study, the peak
incidence was in the second decade of life with a slight
preponderance for males (58%). The sites of occurrence
in order of incidence were: the adrenal gland (90%),
extra-adrenal chromaffin tissue in the abdomen, urinary
bladder, thorax and mediastinum. Odd locations for
phaeochromocytoma, including the neck, heart, sper-
matic cord, vagina and sacrococcygeal region, have been
mentioned in the literature.11
Phaeochromocytoma occurs sporadically, but in about
10% of cases are associated with certain familial disor-
ders that include three autosomal dominant disorders,
MEN 2A (medullary carcinoma thyroid, phaeochro-
mocytoma and hyperparathyroidism) and MEN 2B
(mucosal neuromas and marfanoid habitus along with
medullary carcinoma of the thyroid, phaeochromocytoma
and hyperparathyroidism). In Von Recklinghausen’s neur-
ofibromatosis, the incidence of phaeochromocytoma
is about 1%. In Von Hippel Lindau syndrome phaeo-
chromocytoma is associated with its major manifesta-
tions such as haemangioblastoma of the central nervous
system, retinal angiomas, renal cysts and carcinomas,
pancreatic cyst and epididymal cystadenomas.12
The symptoms of phaeochromocytoma are wide rang-
ing and they are chiefly attributed to the excessive circu-
lating catecholamines. Hypertension is the single most
consistent manifestation.12 The other symptoms include
headache, sweating, palpitation, attacks of anxiety, nausea,
vomiting, abdominal or chest pain, blurred vision, poly-
dipsia and syncopal attacks.
Once phaeochromocytoma is suspected, biochemi-
cal testing can establish the diagnosis in more than 95%
of patients.12 There are several biochemical tests avail-
able for the diagnosis of phaeochromocytoma, which
demonstrate the excessive production of catecholamines.
Opinion is divided as to the best biochemical test for
confirmation of the diagnosis. With the combination of
24-hour urinary VMA and metanephrine measurement,
less than 2% of phaeochromocytomas have been missed.9
Urinary NA, urinary A, plasma NA and plasma A estima-
tion can also establish the diagnosis in most of the cases
of phaeochromocytoma. Of the various biochemical
tests, plasma and urinary catecholamines and urinary
total metanephrines appear to have the highest sensi-
tivity and VMA, the lowest.3,4 This was substantiated
by Peplinski and Norton, who showed that 24-hour
urinary metanephrine level is the single best bio-
chemical indicator of phaeochromocytoma.13 In our
cases, we performed resting plasma catecholamines,
24-hour urinary VMA and fractionated urinary
catecholamaines. Of these, 24-hour VMA was found
to be raised in 85%, fractionated urinary catechola-
mines were raised in 60% and plasma catecholamines
were raised in 80% of cases.
After biochemical confirmation of the phaeo-
chromocytoma, tumour localization was done by radio-
logical imaging techniques, which helped the surgeon in
planning the surgical strategy. Three kinds of imaging
techniques are currently in use: 1) CT, 2) MRI and 3) MIBG
scanning. Current-generation CT can visualize normal
adrenal glands and detect tumours larger than 1 cm. It can
also detect and localize extra-adrenal phaeo-
chromocytomas. Recently, MRI has become the alterna-
tive to CT in localizing phaeochromocytoma and has
several advantages. It does not require intravenous con-
trast administration and the risk of radiation is nil. We
have very little experience with MRI. In two patients with
phaeochromocytoma, it was confirmatory. The other
localizing imaging modality is scintigraphy with [131I]
MIBG, which localizes phaeochromocytoma and also
provides the functional characterization of the tumour.
We have no experience with this modality of investigation.
Selective angiography can also accurately demonstrate
the presence of phaeochromocytoma. With the advent of
more noninvasive techniques such as CT and MRI, the
role of angiography has become questionable. This is an
invasive technique, which can precipitate a hypertensive
crisis. Moreover, angiography cannot demonstrate
hypovascular tumours.
With adequate preoperative preparation, postopera-
tive outcome has become remarkably good, with no
mortality and minimal morbidity.14 Previously, without
adequate preoperative preparation, the operative mortal-
ity reported was as high as 30% to 40%.15 With routine
preoperative preparation, the mortality rate has decreased
from 5.5% to 0% in recently reported series.16–18 Preop-
erative alpha blocker has been used routinely in preop-
erative preparation of phaeochromocytoma. This is now
universally accepted and practised. The commonly used
alpha blocker is phenoxybenzamine hydrochloride, with
an initial dose of 10 mg twice a day. The dose is increased
in a stepwise pattern every day, until an optimum dosage
and blood pressure control along with alpha blockade is
achieved. The rationale for the use of an alpha blocker is
that it causes non-competitive alpha-adrenergic blockage
and permits expansion of intravascular volume and
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reduces the frequency and severity of intraoperative pres-
sor episodes.19,20 Recently, more specific alpha1-adrener-
gic receptor antagonists have been used for preoperative
preparation of phaeochromocytoma patients. Prazosin
hydrochloride (minipres), a selective alpha-1-adrenergic-
receptor antagonist, in doses of 2 to 5 mg three or four
times daily, has been shown to be an excellent drug for
preoperative preparation of phaeochromocytoma.21 In
our study, we used phenoxybenzamine hydrochloride
in 17 patients with good results. We used prazosin
hydrochloride with excellent results in the last nine
patients. Controversy still exists in the routine use of
beta-blocking agents preoperatively. If tachycardia or
cardiac arrhythmias are a problem, a beta-blocker
should definitely be used. Calcium channel blockers
can also be used to control blood pressure in the
preoperative period in refractory cases.22
Patients with phaeochromocytoma may have reduced
circulating plasma volume and sometimes a reduced
red cell volume. This causes a high plasma volume
requirement both during and after surgery. If patients
are not appropriately prepared preoperatively with alpha-
adrenergic blockade and expansion of intravascular
volume, they go into severe hypotension immediately
following resection of the tumour. We try to restore the
plasma volume by giving blood and plasma in the preop-
erative period once alpha-blockade is achieved and dur-
ing the early part of surgery. During surgery, blood and
plasma replacement always exceeds measured blood
loss by at least 0.5 L.
Anaesthetic management for the resection of
phaeochromocytoma has undergone a tremendous
change in the preceding decade and has resulted in very
safe resections. Intra-operative monitoring has become
more extensive and both central venous and arterial
pressure monitoring is done. Sodium nitroprusside is
given intravenously to manage the wide fluctuation of
blood pressure during the intraoperative period of tu-
mour manipulation. Cardiac arrhythmias during surgery
are usually managed with cardio-selective beta-blockers
such as esmolol or with lidocaine.23
Traditionally, anterior trans-abdominal exploration
for phaeochromocytoma excision has been advocated as
the standard operative procedure.24,25 This approach
gives access to the site where the tumour is situated and
also permits thorough exploration of the entire abdominal
cavity. In our study, we used the anterior trans-abdominal
approach in all 26 patients with excellent results.
Nonetheless, some authors claimed that a flank extra-
peritoneal approach is justified in selected groups of
patients.26,27 The development and rapid implementation
of CT, MRI and MIBG scanning for the imaging of adrenal
glands and the accurate localization of phaeo-
chromocytoma preoperatively has allowed consideration
of this approach. This approach is justified mainly in
sporadic and intra-adrenal phaeochromocytoma.
Phaeochromocytoma in association with MEN 2 or in
ectopic locations is better approached by the old, but
time-honoured midline trans-abdominal route. Recently,
laparoscopic adrenalectomy for phaeochromocytoma
has been increasingly reported, although it is associated
with higher morbidity because of technical difficulty
encountered, due to the large size of the tumour.28
However, in small selected tumours, laparoscopic exci-
sion is an option.29
Complete surgical excision is the definitive treatment
for phaeochromocytoma. The goal is cure by total
excision of all tumour deposits. This holds true for both
adrenal as well as extra-adrenal phaeochromocytomas.
The surgeon should inspect both the adrenals and
their fossae, pelvis, the entire length of the inferior
vena cava and the abdominal aorta for phaeochro-
mocytoma. Minimum manipulation of the tumour and
early ligation of the tumour's venous channels are
recommended to reduce the catecholamine output
and precipitation of hypertensive crises. On the right
side, the adrenal vein is very short, wide and directly
opens into the vena cava, so control of the venous system
should be done carefully and very early. The blood
pressure immediately falls on resection of the tumour. In
the case of unilateral adrenal tumour, tumour excision
with unilateral adrenalectomy should be performed.
In the case of bilateral adrenal tumours and phaeo-
chromocytoma in MEN 2, there is considerable debate
about the optimal treatment. The risk of recurrent and
overlooked phaeochromocytoma must be weighed
against the risk of an Addisonian crisis after bilateral
adrenalectomy. Some authors have recommended
preventive bilateral adrenalectomy because of uncom-
plicated life-long adreno-cortical substitution.30,31
Others recommend leaving the vascularized cortical
tissue to preserve the adrenocortical function.32,33 In
cases of malignant lesions, tumour excision, or at least
tumour debulking, should be attempted. Chemotherapy
and radiotherapy have a very little role in malignant
phaeochromocytoma.
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CONCLUSION
Phaeochromocytoma continues to present consider-
able diagnostic and management problems. Surgical treat-
ment could be expeditiously performed for patients with
a correct pre-operative diagnosis and adequate phar-
macological preparation. Exclusive trans-abdominal
approach for surgical resection of both adrenal and extra-
adrenal phaeochromocytoma can be accomplished safely
and with relatively few serious complications. Patients
should be monitored for persistent hypertension.
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